Spectral Medical Inc T.EDT

Looking forward to...

[mercedesman]

...an update from the Company prior to, and or at, the AGM,  as to:

• expected enrollment rates going forward, that takes into account new sites, any re-newed and or re-focussed trial efforts, other new strategic efforts to jump-start the trial, etc. as might have be discussed recently at the Board level.
• an honest assessment of whether 90 patients can be achieved by  late 2023 or early 2024 (another 9 -15 months?) at which point Baxter is due to provide another intallment in it's ($ 10M + USD ?) overall funding assistance as it relates to Tigris Trial completion (not including it's recent multi-million quasi-equity infusion).  With 38 patients needed (as of Feb 2023) for 60% enrollment (Interim Data Review) 9 months would require an average of just over 4 patients per month. 15 months would require an average of 2.5 patients per month (for all sites in total).  Shareholders deserve a realistic and currently achievable time to completion estimate, given the current state of ICU research Trials in the US, and in particular any new strategies being implemented to improve enrolment.
• learning how key executive compensation plans (e.g  PSU's) might have been increased and or altered given a slower than expected post-Covid pace to Tigris completion of late.
• an update on the Company's efforts to bring more investor awareness to Spectral, PMX, it's iDialco assets, etc.  - particularly south of the border.  This speaks directly to the efficiency & effectiveness of future cash raises. and minimizing dilution on the way to completion of the Tigris Trial.

MM

[jonnieboy]

I think that is pretty much all any of us want..........    jonnieboy

[mercedesman]

It's pretty much the minimum that is owed to shareholders that have stuck with them over the years. Last I chekced, Board members are appointed for a reason. I'm always wary of tree-dwellers taking acrimonious anonymous pot-shots from afar (i.e on a public forum) Long and strong the science = PMX particularly in combination with a companion diagnostic to lower the unacceptably